With a market cap of $124.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company. The Boston, Massachusetts-based company engages in developing and commercializing therapies for treating cystic fibrosis (CF).

Shares of Vertex Pharmaceuticals Inc. VRTX slid 1.20% to $485.72 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 1.78% to 5,